

At Seqirus, we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year.
Seqirus has 3000 employees in 3 locations. 1 employee at Seqirus has reviewed Seqirus across various culture dimensions, providing their opinions on items ranging from executive ratings to the pace at work. The latest review was months ago.
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 3,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries.




Tell Seqirus you're interested in working at the company, while keeping your personal identity anonymous. Comparably will give Seqirus the opportunity to hire you. When there's a job opening that's a fit we'll make the match happen.
In 2019, Seqirus applied for 4 H1B visas. Of the work permits applied for, 100% were approved.
Seqirus has a total of 3000 employees
H1B Applications Outcome
This data was calculated using publicly sourced data from OFLC Performance Data
| 0% | Promoters |
|---|---|
| 100% | Passives |
| 0% | Detractors |


Send them an invite to rate the company culture.